Elanco Animal Health (ELAN) to Release Earnings on Tuesday

Elanco Animal Health (NYSE:ELAN) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Elanco Animal Health to post earnings of $0.16 per share and revenue of $1.01 billion for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Elanco Animal Health Trading Down 1.0 %

Shares of NYSE:ELAN opened at $11.02 on Monday. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $5.45 billion, a PE ratio of 27.54, a P/E/G ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 12-month low of $10.77 and a 12-month high of $18.80. The business’s fifty day simple moving average is $11.80 and its 200-day simple moving average is $13.10.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. UBS Group assumed coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 target price for the company. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 29th. Barclays increased their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.